|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
SCºÎ¼ RA °æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
12.05 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
BDºÎ¼ BD Manager ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CTA I/II, Sr.CTA
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CTA/CRC |
1³â¡è |
ä¿ë½Ã |
03.02 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.02 |
|
|
½ÎÀÌÁ¨ÄÚ¸®¾Æ |
[¿Ü±¹°è Á¦¾à] Á¤±ÔÁ÷ ¸¶ÄÉÆà Product Manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
03.15 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CTA I/II, Sr.CTA
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CTA/CRC |
1³â¡è |
ä¿ë½Ã |
02.08 |
|
|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMPÀÎÁõ ÄÁ¼³ÅÏÆ® ¸ðÁý(ÀÇ·á±â±â)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
02.04 |
|
|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMP&Validation ä¿ë°ø°í
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
04.23 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] °æ·Â Clinical Research Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
01.28 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] °æ·Â Project Managerä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
01.28 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] MW&RESºÎ¼ MW ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.17 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
[ÇØ¿Ü¿µ¾÷] ÆÀÀå / ÆÀ¿ø °æ·ÂÁ÷ ¸ðÁý
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
10³â¡è |
ä¿ë½Ã |
12.14 |
|
|
¿ÍÀ̺극ÀÎ |
[ÀÇ·á±â±â] Çã°¡ÀÓ»ó °ü¸® ´ã´çÀÚ Ã¤¿ë(CRM/Clinical operat
°æ±â ¼º³²½Ã ¼öÁ¤±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.18 |
|
|
(ÁÖ)¿ì¿µ¸ÞµðÅØ |
ÀÇ·á±â±â ¸¶ÄÉÅÍ & specialist¸¦ ¸ð½Ê´Ï´Ù
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.16 |
|
|
(ÁÖ)¿¡½º¿¤¸ÞµðÄɾî |
Çؿܹ«¿ª °æ·ÂÁ÷ ä¿ë
¼¿ï µ¿ÀÛ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
1³â¡è |
ä¿ë½Ã |
08.22 |
|